Gritstone Oncology, Inc. (GRTS)
| Market Cap | 457.21M |
| Revenue (ttm) | 4.04M |
| Net Income (ttm) | -105.31M |
| Shares Out | 37.79M |
| EPS (ttm) | -2.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 23 |
| Last Price | $9.25 |
| Previous Close | $9.31 |
| Change ($) | -0.06 |
| Change (%) | -0.64% |
| Day's Open | - |
| Day's Range | 9.15 - 9.25 |
| Day's Volume | 10,526 |
| 52-Week Range | 2.54 - 35.20 |
– Preliminary Data from Phase 1 Study of CORAL Expected Mid-year –
Why? They're focusing on one of the biggest coronavirus problems.
They're off to a good start.
Here's why these highfliers could have more fuel in the tank.
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 0.00% and 12.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunother...
EMERYVILLE, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease imm...
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are you a high-risk stock picker or cautious investor? No matter your answer, there's a stock for you on this list.
Gilead Sciences announced a partnership in HIV with Gritstone Oncology, and upped its stake in Arcus Biosciences. Biotech stock Arcus jumped, but Gritstone fell at the stock market's close.
FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next genera...
Gritstone Oncology (GRTS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Bank of America and Netflix
The coronavirus presents one big risk in the future. This vaccine maker is tackling it.
Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.
— Deal provides nonexclusive access to Genevant's leading LNP technology for use in Gritstone's self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in...
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...
Gritstone's COVID-19 vaccine may have a critical role to play in halting the ongoing pandemic.
--Gritstone to Host Conference Call Today at 8:00 a.m. ET-- EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developi...
--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing-- --Executed Additional PIPE Financing of $15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Gritstone...
EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight mu...
Shareholders of 36KR Holdings Inc (NASDAQ:KRKR) and Gritstone Oncology Inc (NASDAQ:GRTS) have seen their holdings tumble more than 59% over the past 12 months, but analysts still recommend to buy these ...
EMERYVILLE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight mu...
-- The Phase 1 portion s of the stud ies are closed for enrollment ; patient trea tment and follow -up for efficacy and safety continues -- EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Gritston...
EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology , Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fi...
EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight...
It's Time To Buy Gritstone Oncology As First Vaccine Treated Colorectal Cancer Patient Nears RECIST Confirmed Response
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 10.39% and -59.33%, respectively, for the quarter ended June 2020.
EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight ...
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight mult...
Despite The Fall Gritstone Oncology Phase 1 Results Reveal The Efficacy Signal I've Been Looking For
Despite The Fall Gritstone Oncology Phase 1 Results Reveal The Efficacy Signal I've Been Looking For
If there’s one thing that's been made more clear, it’s that the stock market and economy are not reflections of each other. An overbought stock market will eventually turn to the downside, and our deep ...
EMERYVILLE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight ...
Gritstone Oncology (GRTS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Gritstone Oncology Inc (GRTS) delivered earnings and revenue surprises of 14.46% and 5.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight m...
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -1.32% and -26.33%, respectively, for the quarter ended December 2019.
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -13.24% and -18.00%, respectively, for the quarter ended September 2019.
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
-Poster Presentation at SITC 2019 Annual Meeting-
EMERYVILLE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight ...
EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight mul...
EMERYVILLE, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight...
The pricing of a secondary stock offering is taking a toll on the biotech stock.
About GRTS
Gritstone Oncology, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors,... [Read more...]
| Industry Biotechnology | IPO Date Sep 28, 2018 |
| CEO Andrew Allen | Employees 169 |
| Stock Exchange NASDAQ | Ticker Symbol GRTS |
Financial Performance
In 2020, GRTS's revenue was $4.04 million, a decrease of -7.51% compared to the previous year's $4.37 million. Losses were -$105.31 million, 11.5% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for GRTS stock is "Buy." The 12-month stock price forecast is 25.33, which is an increase of 173.84% from the latest price.